189 related articles for article (PubMed ID: 15310300)
1. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
[TBL] [Abstract][Full Text] [Related]
2. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
[TBL] [Abstract][Full Text] [Related]
3. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
4. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
5. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA.
Miyajima Y; Horibe K; Fukuda M; Matsumoto K; Numata S; Mori H; Kato K
Cancer; 1996 Mar; 77(6):1214-9. PubMed ID: 8635146
[TBL] [Abstract][Full Text] [Related]
6. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
7. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
Fukuda M; Miyajima Y; Miyashita Y; Horibe K
J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
9. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
Corrias MV; Faulkner LB; Pistorio A; Rosanda C; Callea F; Piccolo MS; Scaruffi P; Marchi C; Lacitignola L; Occhino M; Gambini C; Tonini GP; Haupt R; De Bernardi B; Pistoia V; Garaventa A
Clin Cancer Res; 2004 Dec; 10(23):7978-85. PubMed ID: 15585633
[TBL] [Abstract][Full Text] [Related]
10. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
12. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology.
Pagani A; Macri L; Faulkner LB; Tintori V; Paoli A; Garaventa A; Bussolati G
Diagn Mol Pathol; 2002 Jun; 11(2):98-106. PubMed ID: 12045713
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
[TBL] [Abstract][Full Text] [Related]
14. Measurement of tyrosine hydroxylase transcripts in bone marrow using biopsied tissue instead of aspirates for neuroblastoma.
Lee ST; Suh YL; Ko YH; Ki CS; Sung KW; Kim HJ; Kim JW; Kim SH; Chueh H; Lee SH; Yoo KH; Koo HH
Pediatr Blood Cancer; 2010 Aug; 55(2):273-8. PubMed ID: 20582938
[TBL] [Abstract][Full Text] [Related]
15. [Supersensitive detection of tyrosine hydroxylase mRNA and neuroblastoma cells by reverse transcription and polymerase chain reaction].
Naito H
Hokkaido Igaku Zasshi; 1991 Mar; 66(2):135-41. PubMed ID: 1676393
[TBL] [Abstract][Full Text] [Related]
16. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
[TBL] [Abstract][Full Text] [Related]
17. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
[TBL] [Abstract][Full Text] [Related]
18. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
19. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
[TBL] [Abstract][Full Text] [Related]
20. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]